Vera Therapeutics (NASDAQ:VERA) Given New $43.00 Price Target at Wedbush

Vera Therapeutics (NASDAQ:VERA) had its target price hoisted by Wedbush from $35.00 to $43.00 in a research report report published on Wednesday, Marketbeat reports. They currently have a neutral rating on the stock.

A number of other analysts have also recently weighed in on VERA. Wolfe Research upgraded shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 target price for the company in a report on Wednesday, March 11th. Guggenheim upped their target price on Vera Therapeutics from $56.00 to $76.00 and gave the company a “buy” rating in a report on Wednesday. TD Cowen reiterated a “buy” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Evercore set a $91.00 price target on Vera Therapeutics in a research report on Friday, May 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Monday, April 20th. Eleven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $84.58.

Vera Therapeutics Price Performance

Shares of NASDAQ VERA opened at $42.43 on Wednesday. Vera Therapeutics has a twelve month low of $19.07 and a twelve month high of $56.05. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $3.05 billion, a price-to-earnings ratio of -7.66 and a beta of 0.92. The firm has a 50-day moving average of $36.40 and a two-hundred day moving average of $41.16.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period in the prior year, the business earned ($0.81) EPS. As a group, analysts expect that Vera Therapeutics will post -6.23 earnings per share for the current fiscal year.

Insider Activity at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $37.93, for a total transaction of $701,705.00. Following the transaction, the chief executive officer owned 198,244 shares in the company, valued at approximately $7,519,394.92. The trade was a 8.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 59,951 shares of company stock valued at $2,392,387 over the last ninety days. Company insiders own 15.90% of the company’s stock.

Hedge Funds Weigh In On Vera Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC increased its holdings in shares of Vera Therapeutics by 50.5% in the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after purchasing an additional 236 shares during the period. Los Angeles Capital Management LLC purchased a new position in shares of Vera Therapeutics during the 4th quarter valued at $46,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Vera Therapeutics during the 4th quarter valued at $71,000. Quantbot Technologies LP acquired a new position in shares of Vera Therapeutics in the second quarter worth $51,000. Finally, Sandia Investment Management LP acquired a new position in shares of Vera Therapeutics in the fourth quarter worth $127,000. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Key Vera Therapeutics News

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: The FDA approved TRUTAKNA for primary IgA nephropathy, making it the first and only available therapy targeting both BAFF and APRIL for this kidney disease. Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA for Adult Patients with Primary IgA Nephropathy
• Positive Sentiment: Multiple reports said the approval triggered a sharp move in the stock, with investors viewing the drug approval as a key commercial catalyst for Vera Therapeutics. US FDA approves Vera’s kidney disease drug
• Positive Sentiment: Analysts responded favorably after the approval, including HC Wainwright raising its price target to $125 and Bank of America lifting its target to $70, reinforcing expectations for meaningful upside if TRUTAKNA gains traction.
• Neutral Sentiment: Wedbush also increased its price target to $43 and kept a neutral rating, suggesting the approval improved sentiment but left some analysts more cautious on valuation.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.